Triazole-Based Alzheimer’s Therapeutics
Tech ID
P27-1314
Patent Status
Granted in India
Design Status
--
Technical Description
This technology describes the multitarget triazole-bridged cycloaryl analogues with dual cholinesterase inhibition, neuroprotective effects, and anti-amyloid β aggregation for Alzheimer’s disease treatment.
Problems Addressed
- Limited Therapeutic Options
- Ineffective Multi-Target Inhibition
- Unsuccessful Drug Trials
- Inadequate Neuroprotection
- High Disease Burden
- Absence of Novel Pharmacophores
TARGET AUDIENCE
- Pharmaceutical & Drug Development Companies
- Biotech & Therapeutics Sector
- Neuroscience & Neurology Research Centers
- Clinical & Healthcare Institutions
- Academic & Research Institutions
TECH FEATURES
- Enhanced Dual Cholinesterase Inhibition
- Efficient Aβ Aggregation Prevention
- Optimized Blood-Brain Barrier Permeability
- Advanced Neuroprotective Properties
- Multifunctional Hybrid Analogues
- Innovative Synthesis Approach
P27-1314
Send download link to email.
Available For
Available for exclusive and non exclusive license
Sell off
Cost
—
Stage of Developments
Technology Validated
Contact Person
Mr. Lalit Ambastha
IP Bazzaar Technology Pvt. Ltd.
IP Bazzaar Technology Pvt. Ltd.
12 First Floor, National Park, Lajpat Nagar-IV,
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com
New Delhi-110024, India
Tel: [+91] 11-26360036;
Fax: [+91] 11-26360037;
Mobile: [+91]9811367838;
Email: tech@ipbazzaar.com;
www.ipbazzaar.com